Cerity Partners LLC Has $134.82 Million Stock Holdings in Amgen Inc. $AMGN

Cerity Partners LLC decreased its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 1.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 411,873 shares of the medical research company’s stock after selling 4,309 shares during the quarter. Cerity Partners LLC’s holdings in Amgen were worth $134,815,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in the business. LPL Financial LLC lifted its holdings in Amgen by 3.6% during the 4th quarter. LPL Financial LLC now owns 1,183,152 shares of the medical research company’s stock valued at $387,257,000 after purchasing an additional 41,188 shares during the last quarter. Erste Asset Management GmbH lifted its holdings in Amgen by 70.1% during the 4th quarter. Erste Asset Management GmbH now owns 156,728 shares of the medical research company’s stock valued at $51,658,000 after purchasing an additional 64,566 shares during the last quarter. Brandywine Global Investment Management LLC lifted its holdings in Amgen by 15.6% during the 4th quarter. Brandywine Global Investment Management LLC now owns 427,722 shares of the medical research company’s stock valued at $139,998,000 after purchasing an additional 57,626 shares during the last quarter. O Shaughnessy Asset Management LLC lifted its holdings in Amgen by 25.7% during the 4th quarter. O Shaughnessy Asset Management LLC now owns 132,386 shares of the medical research company’s stock valued at $43,331,000 after purchasing an additional 27,035 shares during the last quarter. Finally, Hilton Head Capital Partners LLC acquired a new stake in Amgen during the 4th quarter valued at $1,243,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on AMGN shares. UBS Group raised their price target on Amgen from $390.00 to $400.00 and gave the company a “buy” rating in a report on Monday, April 13th. Barclays started coverage on Amgen in a report on Friday, February 20th. They set an “equal weight” rating and a $350.00 price target for the company. Guggenheim cut their price target on Amgen from $351.00 to $340.00 and set a “neutral” rating for the company in a report on Monday, May 4th. Wells Fargo & Company raised their price target on Amgen from $375.00 to $390.00 and gave the company an “equal weight” rating in a report on Thursday, March 19th. Finally, Canaccord Genuity Group initiated coverage on Amgen in a report on Monday, April 20th. They set a “hold” rating and a $366.00 price target for the company. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, fourteen have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $353.81.

Insider Buying and Selling at Amgen

In other news, SVP Nancy A. Grygiel sold 1,237 shares of Amgen stock in a transaction on Monday, May 4th. The stock was sold at an average price of $323.73, for a total transaction of $400,454.01. Following the completion of the sale, the senior vice president owned 7,009 shares of the company’s stock, valued at approximately $2,269,023.57. This trade represents a 15.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.85% of the company’s stock.

Amgen Stock Down 1.1%

AMGN opened at $345.66 on Tuesday. Amgen Inc. has a fifty-two week low of $267.83 and a fifty-two week high of $391.29. The company has a debt-to-equity ratio of 5.65, a quick ratio of 1.01 and a current ratio of 1.26. The company has a market capitalization of $186.56 billion, a P/E ratio of 24.05, a P/E/G ratio of 3.51 and a beta of 0.42. The stock has a fifty day moving average of $341.20 and a 200-day moving average of $345.51.

Amgen (NASDAQ:AMGN) last posted its earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, topping analysts’ consensus estimates of $4.77 by $0.38. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The company had revenue of $8.62 billion during the quarter, compared to the consensus estimate of $8.58 billion. During the same quarter last year, the firm earned $4.90 earnings per share. The company’s revenue was up 5.8% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, equities analysts expect that Amgen Inc. will post 22.38 EPS for the current year.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.